GlaxoSmithKline reported a sharp drop in net profit for the second quarter, reflecting the increased dominance of lower-margin vaccines and over-the-counter medicines in the company’s portfolio following its $20 billion asset swap with Novartis.
from WSJ.com: US Business http://ift.tt/1OBuv6O
via IFTTT
No comments:
Post a Comment